Agenus Inc. (NASDAQ: AGEN) is an immunology company focused on the discovery and development of novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. Using its proprietary platforms Retrocyte Display™ and SECANT®, the company is currently developing novel antibodies to target a collection of checkpoint proteins – including GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1 and other undisclosed checkpoints in partnered and internal programs. Agenus’s development pipeline includes Prophage, a heat shock protein vaccine that’s successfully completed phase II studies for the treatment of newly diagnosed glioblastoma multiforme. For more information, visit the company’s website at www.agenusbio.com.